XORTX to delist shares from TSX Venture Exchange

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange while maintaining its listing on Nasdaq.

Accepted by SEC EDGAR 06/12/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange while maintaining its listing on Nasdaq. The board-approved decision follows a review that found the costs, administrative burden, and differing regulatory environments of a dual listing were not justified.

The company expects the delisting to eliminate duplicative exchange fees, reduce legal and accounting expenses, and simplify regulatory requirements, allowing management to focus more on advancing its XRx-026 gout program and other kidney disease therapies. Shareholders, including those in Canada, will continue to have full trading access to XORTX shares on Nasdaq, and no shareholder action is required.

Insights

Cross-border listing & biotech capital markets analyst

XORTX is consolidating its listing on Nasdaq to cut costs and complexity.

XORTX is voluntarily delisting from the TSX Venture Exchange while keeping its Nasdaq listing. The company cites duplicative exchange fees, legal and accounting costs, and differing regulatory regimes as reasons for ending its dual listing structure.

This move concentrates trading in one primary market and may streamline future financing and compliance efforts, particularly as XORTX emphasizes development of its XRx-026 gout program and other kidney disease candidates. Actual effects on liquidity and investor base will depend on how trading volume and institutional interest evolve on Nasdaq alone.

Key Terms

voluntarily delist, TSX Venture Exchange, reporting issuer, forward-looking statements, +1 more

5 terms

voluntarily delist regulatory

"announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange"

A company chooses to remove its shares from a stock exchange of its own accord, stopping regular public trading while it may still exist as a private business. For investors this matters because liquidity and transparency usually fall—selling shares becomes harder and public reporting standards may be reduced—so the move can change how easy it is to buy or sell stock and how much reliable information is available about the company.

TSX Venture Exchange regulatory

"voluntarily delist its common shares from the TSX Venture Exchange"

A junior stock exchange in Canada where smaller, early-stage companies list shares to raise capital and gain public visibility. Think of it as a farmers’ market for young businesses: it offers investors a chance to buy into fast-growing but higher-risk ventures, with looser listing rules and typically lower liquidity than major exchanges. It matters because performance and financing on this exchange can signal growth prospects or risk for investors.

reporting issuer regulatory

"XORTX will continue to be a reporting issuer under applicable securities laws in Alberta, British Columbia and Ontario"

A reporting issuer is a company or investment fund legally required to provide regular, public financial and corporate updates to securities regulators and investors. For investors it matters because those routine filings act like a business’s recurring health reports—offering consistent, official information to assess performance, risks and value so people can make informed buy, sell or compare decisions.

forward-looking statements regulatory

"This press release contains express or implied forward-looking statements pursuant to applicable securities laws"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Nasdaq listing standards regulatory

"Such risks, uncertainties, and other factors include, but are not limited to our ongoing compliance with Nasdaq listing standards"

Nasdaq listing standards are the set of rules a company must meet to be admitted to and remain on the Nasdaq stock market, covering financial thresholds (like minimum share price and earnings), reporting and disclosure, and board and governance practices. They matter to investors because meeting these standards signals a baseline of financial health and transparency, reduces the risk of sudden delisting, and helps ensure a market with enough buyers and sellers—like a safety checklist that keeps the trading venue orderly and trustworthy.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did XORTX Therapeutics (XRTX) announce in this Form 6-K?

XORTX announced it has elected to voluntarily delist its common shares from the TSX Venture Exchange. The company will remain listed on Nasdaq, and will provide additional timing details for the TSXV delisting in a separate press release.

Will XORTX Therapeutics (XRTX) remain listed on Nasdaq after the TSXV delisting?

Yes, XORTX will continue to have its common shares listed and traded on Nasdaq. The company states that all shareholders, including Canadian investors, will retain full trading access to their shares through the Nasdaq listing.

Why is XORTX Therapeutics (XRTX) voluntarily delisting from the TSX Venture Exchange?

XORTX determined that maintaining a dual listing on the TSXV no longer justified the associated costs and administrative requirements. It also cited challenges from differing regulatory environments and aims to reduce duplicative fees, legal and accounting expenses, and regulatory complexity.

Does the TSXV delisting require shareholder approval for XORTX Therapeutics (XRTX)?

Shareholder approval is not required for the voluntary TSXV delisting. Under TSXV policies, no shareholder vote is needed because XORTX’s common shares are already listed on an acceptable alternative market, namely Nasdaq.

Do XORTX Therapeutics (XRTX) shareholders need to take any action due to the TSXV delisting?

No action is required from shareholders regarding the voluntary TSXV delisting. XORTX notes that investors will continue to have full trading access on Nasdaq and should contact their brokers only if they have account-specific questions.

How does the TSXV delisting relate to XORTX’s kidney and gout drug programs?

XORTX believes ending the TSXV listing will free management to focus more on its XRx-026 gout program and other kidney disease candidates. The company expects fewer regulatory and administrative demands to support long-term development and potential value creation efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

EXHIBIT INDEX

99.1 News release dated June 12, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)
Date: June 12, 2026		By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT 99.1

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

This decision was taken following a comprehensive evaluation, the Company determined that maintaining a dual listing on the TSXV does not justify the associated costs and administrative requirements and presents challenges due to the different regulatory environments. It is envisioned that the voluntary delisting will eliminate duplicative exchange fees, reduce legal and accounting expenses, optimize company financing initiatives and minimize regulatory complexity, and enable greater management focus on the advancement of the XRx-026 program for the treatment of gout for long-term shareholder value creation.

All shareholders, including Canadian shareholders, will continue to maintain full trading access of their common shares on Nasdaq. No action is required by shareholders in connection with the voluntary delisting. Shareholders with account-specific questions are encouraged to contact their respective brokers.

The voluntary delisting from the TSXV was approved by the Company's Board of Directors. In accordance with TSXV policies, shareholder approval is not required as the Company’s common shares are listed on an acceptable alternative market. XORTX will continue to be a reporting issuer under applicable securities laws in Alberta, British Columbia and Ontario.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy and recently acquired VB4-P5 program, which is currently at the pre-IND stage of development and targets both rare and prevalent forms of kidney disease. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases.

For more information, please contact:

Allen Davidoff, CEO	Nick Rigopulos, Director of Communications
adavidoff@xortx.com	nick@alpineequityadv.com
+1 403 455 7727	+1 617 901 0785

Neither the TSX Venture Exchange nor Nasdaq has approved or disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to our ongoing compliance with Nasdaq listing standards; the success and timing of our preclinical studies and clinical trials; our plans to develop and commercialize our product candidates; and our plans to advance research in other kidney disease applications. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 6.7 KB